| pubmed-article:17521712 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C0027051 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C0085295 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C0167627 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C0456603 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C1705413 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:17521712 | lifeskim:mentions | umls-concept:C0702240 | lld:lifeskim |
| pubmed-article:17521712 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17521712 | pubmed:dateCreated | 2008-1-14 | lld:pubmed |
| pubmed-article:17521712 | pubmed:abstractText | The balance between pro-inflammatory and anti-inflammatory molecules is likely to modulate the processes that lead to atherogenesis and rapid coronary artery disease progression. We sought to compare the positive predictive values of serum soluble CD40 ligand (sCD40L)/interleukin-10 (IL-10) ratio, versus individual sCD40L, and IL-10 measurements regarding in-hospital events in patients admitted into the hospital with ST-segment elevation myocardial infarction (STEMI). | lld:pubmed |
| pubmed-article:17521712 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17521712 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17521712 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17521712 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17521712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17521712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17521712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17521712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17521712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17521712 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17521712 | pubmed:issn | 0049-3848 | lld:pubmed |
| pubmed-article:17521712 | pubmed:author | pubmed-author:KaskiJuan... | lld:pubmed |
| pubmed-article:17521712 | pubmed:author | pubmed-author:Dominguez-Rod... | lld:pubmed |
| pubmed-article:17521712 | pubmed:author | pubmed-author:Abreu-Gonzale... | lld:pubmed |
| pubmed-article:17521712 | pubmed:author | pubmed-author:Garcia-Gonzal... | lld:pubmed |
| pubmed-article:17521712 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17521712 | pubmed:volume | 121 | lld:pubmed |
| pubmed-article:17521712 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17521712 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17521712 | pubmed:pagination | 293-9 | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:meshHeading | pubmed-meshheading:17521712... | lld:pubmed |
| pubmed-article:17521712 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17521712 | pubmed:articleTitle | Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. | lld:pubmed |
| pubmed-article:17521712 | pubmed:affiliation | Department of Cardiology, Coronary Care Unit, Hospital Universitario de Canarias, Tenerife, Spain. adrvdg@hotmail.com | lld:pubmed |
| pubmed-article:17521712 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17521712 | lld:pubmed |
